enGene Therapeutics Inc. (ENGN)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
EnGene Therapeutics: The Selloff Creates An Opportunity
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data for its sole asset, detalimogene voraplasmid. ENGN's therapy showed only a 25% 12-month complete response rate, underperforming competitors, but boasts a strong safety profile and Fast Track/RMAT status. Risks include FDA rejection and insurers declining coverage due to low efficacy, but current valuation implies limited further downside given the cash position.
enGene Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 13,992 | $24,206 | $23,786.4 | -$419.6 | -1.73% |
 Ilko Menkov Vestal Point Capita LLP | 1.67M | $2.88M | $2.83M | -$50,023.07 | -1.73% |
 Christopher C. Powers Farther Finance Advisors, LLC | 100 | $173 | $179 | $6 | 3.47% |
 David Vollmer PFS Partners, LLC | 11,000 | $19,030 | $19,690 | $660 | 3.47% |
 Raymond Debbane Siren, L.L.C. | 6.26M | $10.82M | $10.64M | -$187,699.86 | -1.73% |
enGene Therapeutics Inc. (ENGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has enGene Therapeutics Inc. ever had a stock split?
enGene Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald H. W. Cooper CEO | NASDAQ (CM) Exchange | 29286X101 CUSIP |
| CA Country | 82 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
enGene Holdings Inc. stands as a vanguard in the sector of biotechnological advancements, focusing its efforts through its subsidiary, enGene, Inc. This clinical-stage biotechnology company has dedicated itself to the development of genetic medicines, emphasizing the targeted delivery of therapeutics to mucosal tissues alongside other vital organs. Incorporated in 2023, enGene Holdings Inc. anchors its operations in Saint-Laurent, Canada, symbolizing a blend of innovative research and steadfast dedication towards addressing some of the most challenging medical conditions faced today.
Products and Services
EG-70 (detalimogene voraplasmid)
This product represents enGene Holdings Inc.'s forefront in its array of offerings, manifesting as a cutting-edge, non-viral immunotherapy. Targeted towards patients suffering from non-muscle invasive bladder cancer, particularly those with carcinoma-in-situ (Cis) who have not responded to the traditional Bacillus Calmette-Guérin treatment, EG-70 stands as a testament to the company's innovative strides in genetic medicine. This lead product candidate epitomizes the company's ambition to revolutionize the treatment landscape for a niche yet significantly impacted patient demographic.
